Cue Biopharma, Inc. (CUE) Fair Value 2026

CUE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-28, Cue Biopharma, Inc. (CUE) trades at $27.88. QOC: 5.8/10. Value Trap Risk: 19/100 (SAFE). 0/13 models active.

Key Facts

Ticker
CUE
Price
$27.88
Quality Score
5.8/10
Value Trap Risk
19/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give CUE?

0 Intrinsic Value Models vs. Current Price ($27.88)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Cue Biopharma, Inc. (CUE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cue Biopharma, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CUE?

0 of 13 models are currently active for CUE. See which stocks rank higher →

How Does CUE Rank in Biotechnology?

Among 625 Biotechnology stocks, CUE ranks #175 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Cue Biopharma, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CUE a Value Trap?

CirclFi's Value Trap algorithm assigns CUE a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Cue Biopharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Cue Biopharma, Inc.'s fundamental quality profile registers 5.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CUE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cue Biopharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CCCCC4 Therapeutics, Inc.QOC 5.8BBOTBridgeBio Oncology Therapeutics, Inc.QOC 5.8ABSIAbsci CorporationQOC 5.8XLOXilio Therapeutics, Inc.QOC 5.8DNAGinkgo Bioworks Holdings, Inc.QOC 5.8INBXInhibrx Biosciences, Inc.QOC 5.8PMVPPMV Pharmaceuticals, Inc.QOC 5.0KLRSKalaris Therapeutics, Inc.QOC 4.3ADMAADMA Biologics, Inc.QOC 8.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CCCC · BBOT · ABSI · XLO · DNA · INBX · PMVP · KLRS · ADMA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CUE?

6 companies across all industries closest to CUE’s Quality of Company score of 5.8/10.

AUGOAura Minerals Inc.QOC 5.8TKNOAlpha Teknova, Inc.QOC 5.8ELLOEllomay Capital Ltd.QOC 5.8AIRGAirgain, Inc.QOC 5.8AIRIAir Industries GroupQOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AUGO · TKNO · ELLO · AIRG · AIRI · NVDA

Where Does CUE Sit in CirclFi's Biotechnology Rankings?

CUE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Cue Biopharma, Inc.’s Valuation?

What is Cue Biopharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Cue Biopharma, Inc. (CUE). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CUE overvalued or undervalued right now?

At $27.88, 0 of 0 active models suggest CUE may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Cue Biopharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.8 mean for CUE?

Cue Biopharma, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CUE?

CirclFi analyzes CUE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CUE a value trap in 2026?

Cue Biopharma, Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Cue Biopharma, Inc. (CUE) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CUE/ · Methodology
Primary sources for this CUE valuation
  • Financial statements: Cue Biopharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001645460) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CUE as of ; valuations recomputed .